Magenta therapeutics - mgta-117 conditioning adc-based program on track for initial clinical data in 2021

Magenta therapeutics - mgta-117 conditioning adc-based program on track for initial clinical data in 2021.magenta therapeutics - mgta-145 stem cell mobilization phase 1 program met all safety and efficacy endpoints.magenta therapeutics inc - cd45-adc progressing in ind-enabling studies.magenta therapeutics - mgta-456 phase 2 trial in inherited metabolic disorders experiencing enrollment delay due to impact of novel coronavirus.magenta therapeutics inc - cash runway extended into 1q22.magenta therapeutics - plans to initiate multiple phase 2 trials of mgta-145, which may be staggered over course of year due to impacts from covid-19.magenta therapeutics - potential for co to present initial phase 2 data on mgta-145 in 2020 as planned.magenta therapeutics - based on covid-19-related impacts at co's clinical sites, mgta-456 phase 2 trial enrollment timelines have been shifted into 2021.magenta therapeutics - mgta-456 phase 2 trial in patients with blood cancers currently expected to complete enrollment in 2020.
DNTH Ratings Summary
DNTH Quant Ranking